Meckstroth Karen R, Darney Philip D
Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco General Hospital, San Francisco, CA 94110, USA.
Best Pract Res Clin Obstet Gynaecol. 2003 Oct;17(5):745-63. doi: 10.1016/s1521-6934(03)00070-1.
Since the 1980s, when mifepristone combined with a prostaglandin was found to be safe and effective for early abortion, many studies have refined the regimens and investigated alternatives such as methotrexate plus misoprostol, and misoprostol alone. Evidence now demonstrates that more than 200 mg of mifepristone provides no additional benefit, that vaginal misoprostol is superior to oral, especially between 7 and 9 weeks' gestation, and that misoprostol may be safely self-administered at home. Buccal and sublingual routes of administration of misoprostol also are promising. Absolute contraindications to medical abortion arise infrequently. Gastrointestinal and other side-effects occur in about one-third of women, primarily after administration of the prostaglandin. Careful assessment before and after medical abortion is essential and can be accomplished in various ways, depending on the skills of the clinician.
自20世纪80年代发现米非司酮与前列腺素联合使用对早期流产安全有效以来,许多研究对用药方案进行了优化,并研究了其他方法,如甲氨蝶呤加米索前列醇以及单独使用米索前列醇。目前有证据表明,超过200毫克的米非司酮并无额外益处,阴道用米索前列醇优于口服,尤其是在妊娠7至9周时,而且米索前列醇可在家中安全地自行给药。米索前列醇的颊部和舌下给药途径也很有前景。药物流产的绝对禁忌症很少出现。约三分之一的女性会出现胃肠道及其他副作用,主要是在使用前列腺素之后。药物流产前后进行仔细评估至关重要,可根据临床医生的技能以多种方式完成。